BioCardia
Business Services · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
320 Soquel Way, Sunnyvale, California, 9...Phone Number
(650) 226-0120Website
www.biocardia.comRevenue
-Stock Symbol
BCDAIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
2
1
1
1
1
About BioCardia
BioCardia is a clinical-stage regenerative medicine company focused on developing novel therapeutics for cardiovascular diseases with significant unmet medical needs. The company is advancing proprietary, comprehensive biotherapeutic solutions through its CardiAMP and CardiALLO therapy programs. Clinical results supporting both programs are compelling and build upon some of the most rigorous data to date in the field, utilizing intramyocardial delivery of marrow-derived cells.Explore more
BioCardia Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is BioCardia your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on BioCardia recently announced quarterly report
Product Launch: Get notified when BioCardia launches new products
Funding: Get notified immidiatlly once BioCardia has new funding data
Check if BioCardia has recently received funding, and reach out quickly before it becomes old news!
BioCardia, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at BioCardia
Click to see if BioCardia had a recent Job posting/layoffs
Check out if BioCardia is spiking on competitors!
Recommended Actions
Find VP level buyers at BioCardia
Find more new buyers
Compare Similar Companies to BioCardia
Compare insights from companies similar to BioCardia, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
BioCardia is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
BioCardia is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about BioCardia.
BioCardia financials insights
Gather financial insights about BioCardia, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2016
Debt
$4.4M
2026
Stock/Share Issuance
$4.4M
BioCardia Tech Stack
A closer look at the technologies used by BioCardia
Most Recent Scoops
Funding
Funding
Partnership
BioCardia is open to partnerships for its Cardialo cell therapy, highlighting its ability to manufacture clinical-grade cells at a competitive cost profile. The company is seeking partnerships for indications not currently being pursued.
Partnership, Healthcare Technology, Manufacturing Operations
Partnership
BioCardia has partnered with Zimmer Biomet for orthopedic applications of its cell processing platform in Japan. The company's Helix catheter system is the only new product to be introduced, and BioCardia views sponsors of other cardiac cell therapies as potential partners for its Helix biotherapeutic delivery system.
Partnership, Healthcare Technology
Partnership
BioCardia is engaged in partnering discussions for its Morph platform in the electrophysiology market, which is valued at over $10 billion per year. The company expects to announce details on a fusion imaging partnership that could benefit all of its product offerings and partnering efforts.
Partnership, Healthcare Technology
Project
Medical Research, Clinical Operations, Healthcare Technology
BioCardia News & Media
BioCardia Inc (BCDA) (Q2 2026) Earnings Call Highlights: Regulatory Wins in Japan and US ...
BioCardia advances toward Japanese Shonin submission and FDA approval pathways while managing cash runway into 2027.BioCardia Reports Second Quarter 2026 Business Highlights and Financial Results
SUNNYVALE, Calif., Aug. 12, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the second quarter 2026 and filed its quarterly report on Form 10-Q for the three and six months ended June 30, 2026 with the Securities and Exchange Commission. The Company will also hold a conference call at 4:30 PM ET today in whichBioCardia to Host Q2 2026 Financial Results and Corporate Update Conference Call on August 12, 2026
SUNNYVALE, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will provide a corporate update and report its financial results for the second quarter of 2026 by conference call on Wednesday, August 12, 2026 at 4:30 PM EDT. Following management’s formal remarks, there will be a question-and-answer session.BioCardia Letter to Stockholders on 2026 Priorities and Strategic Opportunities
SUNNYVALE, Calif., June 18, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that the Company’s Chief Executive Officer, Peter Altman, issued the following letter to shareholders.
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Frequently Asked Questions Regarding BioCardia
Sign Up For FreeTo access detailed company insights
BioCardia is a clinical-stage regenerative medicine company focused on developing novel therapeutics for cardiovascular diseases with significant unmet medical needs. The company is advancing proprietary, comprehensive biotherapeutic solutions through its CardiAMP and CardiALLO therapy programs. Clinical results supporting both programs are compell... Read More
